ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

NCT03117816 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

214

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia in Remission

Interventions

DRUG: AOP2014 / Pegylated-Proline-interferon alpha-2b
OTHER: Surveillance

Sponsor

Philipps University Marburg

Collaborators

[object Object]
[object Object]